Literature DB >> 7664023

Gene therapeutic agents: the use of ribozymes, antisense, and RNA decoys for HIV-1 infection.

J A Smythe1, G Symonds.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7664023     DOI: 10.1007/bf01630480

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


× No keyword cloud information.
  31 in total

1.  A ribozyme with DNA in the hybridising arms displays enhanced cleavage ability.

Authors:  P Hendry; M J McCall; F S Santiago; P A Jennings
Journal:  Nucleic Acids Res       Date:  1992-11-11       Impact factor: 16.971

Review 2.  Zidovudine resistance of human immunodeficiency virus.

Authors:  D D Richman
Journal:  Rev Infect Dis       Date:  1990 Jul-Aug

3.  Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression.

Authors:  J Lisziewicz; J Rappaport; R Dhar
Journal:  New Biol       Date:  1991-01

Review 4.  Human gene therapy.

Authors:  W F Anderson
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

Review 5.  Retroviral reverse transcriptase: synthesis, structure, and function.

Authors:  S P Goff
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

Review 6.  Regulation of HIV-1 gene expression.

Authors:  B R Cullen
Journal:  FASEB J       Date:  1991-07       Impact factor: 5.191

Review 7.  Biological catalysis by RNA.

Authors:  T R Cech; B L Bass
Journal:  Annu Rev Biochem       Date:  1986       Impact factor: 23.643

Review 8.  HIV-1: the infective process in vivo.

Authors:  J M McCune
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

Review 9.  Human gene therapy comes of age.

Authors:  A D Miller
Journal:  Nature       Date:  1992-06-11       Impact factor: 49.962

Review 10.  Molecular biology of the human immunodeficiency virus type 1.

Authors:  W A Haseltine
Journal:  FASEB J       Date:  1991-07       Impact factor: 5.191

View more
  1 in total

Review 1.  Anti-HIV ribozymes.

Authors:  L Q Sun; J A Ely; W Gerlach; G Symonds
Journal:  Mol Biotechnol       Date:  1997-06       Impact factor: 2.860

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.